Rates and patterns of chronic obstructive pulmonary disease exacerbations

Canadian Respiratory Journal

Volumn 11, Issue 8, 2004, Pages 559-564

  de Melo, Magda Nunes ^a   Ernst, Pierre ^b   Suissa, Samy ^b  

^a MCGILL UNIVERSITY   (Canada)

^b ROYAL VICTORIA HOSPITAL   (Canada)

Author keywords

Chronic obstructive pulmonary disease; Pharmacoepidemiology; Rate of exacerbations

Indexed keywords

AMINOGLYCOSIDE ANTIBIOTIC AGENT; ANTIBIOTIC AGENT; CEPHALOSPORIN DERIVATIVE; CORTICOSTEROID; COTRIMOXAZOLE; MACROLIDE; PENICILLIN DERIVATIVE; QUINOLINE DERIVED ANTIINFECTIVE AGENT; TETRACYCLINE DERIVATIVE;

ACUTE DISEASE; ADULT; AGED; ARTICLE; CANADA; CHRONIC OBSTRUCTIVE LUNG DISEASE; COHORT ANALYSIS; CONTROLLED STUDY; DATA BASE; DISEASE EXACERBATION; DISEASE SEVERITY; FEMALE; FOLLOW UP; FREQUENCY ANALYSIS; GROUPS BY AGE; HOSPITAL DISCHARGE; HOSPITALIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; POPULATION RESEARCH; PRESCRIPTION; PRIORITY JOURNAL; SEX DIFFERENCE; TREATMENT OUTCOME;

EID: 11844294660     PISSN: 11982241     EISSN: None     Source Type: Journal    
DOI: 10.1155/2004/813058     Document Type: Article

References (28)

1. Hunter MH, King DE. COPD: Management of acute exacerbations and chronic stable disease. Am Fam Physician 2001;64:603-12.
2. Wedzicha JA. Exacerbations: Etiology and pathophysiologic mechanisms. Chest 2002;121(Suppl 5):136S-41S.
3. Seemungal TA, Donaldson GC, Paul EA, Bestall JC, Jeffries DJ, Wedzicha JA. Effect of exacerbation on quality of life in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1998;157:1418-22.
4. Connors AF Jr, Dawson NV, Thomas C, et al. Outcomes following acute exacerbation of severe chronic obstructive lung disease. The SUPPORT investigators (Study to Understand Prognoses and Preferences for Outcomes and Risks of Treatments). Am J Respir Crit Care Med 1996;154:959-67. Erratum in: 1997;155:386.
5. Weinberger M, Oddone EZ, Henderson WG. Does increased access to primary care reduce hospital readmissions? Veterans Affairs Cooperative Study Group on Primary Care and Hospital Readmission. N Engl J Med 1996;334:1441-7.
6. Garcia-Aymerich J, Farrero E, Felez MA, et al. Risk factors of readmission to hospital for a COPD exacerbation: A prospective study. Thorax 2003;58:100-5.
7. Voelkel N, Tuder R. COPD: Exacerbation. Chest 2000;117(5 Suppl 2):376S-9S.
8. Niederman MS, McCombs JS, Unger AN, Kumar A, Popovian R. Treatment cost of acute exacerbations of chronic bronchitis. Clin Ther 1999;21:576-91.
9. Mannino DM. COPD: Epidemiology, prevalence, morbidity and mortality, and disease heterogeneity. Chest 2002;121(5 Suppl):121S-6S.
10. Stoller JK. Clinical practice. Acute exacerbations of chronic obstructive pulmonary disease. N Engl J Med 2002;346:988-94.
11. Rodriguez-Roisin R. Toward a consensus definition for COPD exacerbations. Chest 2000;117(Suppl 2):398S-401S.
12. Downey W, Beck P, McNutt M, et al. Health databases in Saskatchewan. In: Strom BL, ed. Pharmacoepidemiology. Chichester: John Wiley & Sons Ltd, 2000:325-45.
13. International Classification of Diseases, 9th Revision. Geneva: World Health Organization, 1998.
14. Anthonisen NR, Manfreda J, Warren CP, Hershfield ES, Harding GK, Nelson NA. Antibiotic therapy in exacerbations of chronic obstructive pulmonary disease. Ann Intern Med 1987;106:196-204.
15. Seemungal TA, Donaldson GC, Bhowmik A, Jeffries DJ, Wedzicha JA. Time course and recovery of exacerbations in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2000;161:1608-13.
16. Sethi S, Evans N, Grant BJ, Murphy TF: New strains of bacteria and exacerbations of chronic obstructive pulmonary disease. N Engl J Med 2002;347:465-71.
17. Jones PW, Willits LR, Burge PS, Calverley PM; Inhaled Steroids in Obstructive Lung Disease in Europe study investigators. Disease severity and the effect of fluticasone propionate on chronic obstructive pulmonary disease exacerbations. Eur Respir J 2003;21:68-73.
18. Donaldson GC, Seemungal TA, Patel IS, Lloyd-Owen SJ, Wilkinson TM, Wedzicha JA. Longitudinal changes in the nature, severity and frequency of COPD exacerbations. Eur Respir J 2003;22:931-6.
19. American Thoracic Society. Standards for the diagnosis and care of patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1995;152:S77-121.
20. Sunyer J, Antó JM, McFarlane D, et al. Sex differences in mortality of people who visited emergency rooms for asthma and chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1998;158:851-6
21. Silverman EK, Weiss ST, Drazen JM, et al. Gender-related differences in severe, early-onset chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2000;162:2152-8.
22. Chen Y, Horne SL, Dosman JA. Increased susceptibility to lung dysfunction in female smokers. Am Rev Respir Dis 1991;143:1224-30.
23. Rawson NS, Malcolm E. Validity of the recording of ischaemic heart disease and chronic obstructive pulmonary disease in the Saskatchewan health care datafiles. Stat Med 1995;14:2627-43.
24. Yunginger JW, Reed CE, O'Connell EJ, Melton LJ III, O'Fallon WM, Silverstein MD. A community-based study of the epidemiology of asthma. Incidence rates, 1964-1983. Am Rev Respir Dis 1992;146:888-94.
25. Bourbeau J, Ernst P, Cockcoft D, Suissa S. Inhaled corticosteroids and hospitalisation due to exacerbation of COPD. Eur Respir J 2003;22:286-9.
26. Anto JM, Vermeire P, Vestbo J, Sunyer J. Epidemiology of chronic obstructive pulmonary disease. Eur Respir J 2001;17:982-94.
27. Murray CJL, Lopez AD. Evidence-based health policy - Lessons from the Global Burden of Disease Study. Science 1996;274:740-3.
28. Donaldson GC, Seemungal TA, Bhowmik A, Wedzicha JA. Relationship between exacerbation frequency and lung function decline in chronic obstructive pulmonary disease. Thorax 2002;57:847-52.